Daiwa Securities Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-193
Closed -$1K 1335
2022
Q4
$1K Buy
+193
New +$1.01K ﹤0.01% 1307
2021
Q4
Sell
-58
Closed 1474
2021
Q3
$0 Hold
58
﹤0.01% 1356
2021
Q2
$0 Hold
58
﹤0.01% 1298
2021
Q1
$0 Hold
58
﹤0.01% 1297
2020
Q4
$1K Buy
+58
New +$661 ﹤0.01% 1237
2019
Q4
Sell
-126
Closed -$1K 1262
2019
Q3
$1K Hold
126
﹤0.01% 1169
2019
Q2
$2K Hold
126
﹤0.01% 1162
2019
Q1
$2K Hold
126
﹤0.01% 1148
2018
Q4
$2K Hold
126
﹤0.01% 1116
2018
Q3
$2K Hold
126
﹤0.01% 1135
2018
Q2
$2K Hold
126
﹤0.01% 1152
2018
Q1
$3K Buy
+126
New +$2.8K ﹤0.01% 1108

Daiwa Securities Group's CNCE Position: Q1 2023 in Review

Daiwa Securities Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 193 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in CNCE in Q1 2018 and held it in 12 quarters. The position peaked at $3K in Q1 2018. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

  • Daiwa Securities Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 193 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1K.
  • Daiwa Securities Group first reported a position in Concert Pharmaceuticals, Inc. in Q1 2018 and held it in 12 quarters.
  • Daiwa Securities Group's Concert Pharmaceuticals, Inc. position peaked at $3K in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Daiwa Securities Group's 13F filing for Q1 2023, filed 2 May 2023.